



Exchange Act. o

---

Item 2.02 Results of Operations and Financial Condition.

The information provided pursuant to this Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing or other document filed by the Company pursuant to the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document. The information provided pursuant to this Item 2.02 shall instead be deemed “furnished.”

On March 7, 2018, CTI BioPharma Corp. issued a press release announcing its financial results for the quarter and year ended December 31, 2017 and certain other information. The full text of the press release is set forth in Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
<u>99.1</u>	<u>Press Release of CTI BioPharma Corp., dated March 7, 2018.</u>

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CTI BIOPHARMA CORP.

Date: March 7, 2018 By: /s/ David H. Kirske  
David H. Kirske  
Chief Financial Officer

---

EXHIBIT INDEX

Exhibit  
Description  
No.

99 Press Release of CTI BioPharma Corp., dated March 7, 2018.